CA3064736A1 - Echantillonnage selectif pour evaluer des frequences spatiales structurales avec des mecanismes de contraste specifiques - Google Patents
Echantillonnage selectif pour evaluer des frequences spatiales structurales avec des mecanismes de contraste specifiques Download PDFInfo
- Publication number
- CA3064736A1 CA3064736A1 CA3064736A CA3064736A CA3064736A1 CA 3064736 A1 CA3064736 A1 CA 3064736A1 CA 3064736 A CA3064736 A CA 3064736A CA 3064736 A CA3064736 A CA 3064736A CA 3064736 A1 CA3064736 A1 CA 3064736A1
- Authority
- CA
- Canada
- Prior art keywords
- tissue
- value
- signal
- voi
- para
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000007246 mechanism Effects 0.000 title claims description 57
- 238000005070 sampling Methods 0.000 title description 87
- 210000001519 tissue Anatomy 0.000 claims abstract description 313
- 238000000034 method Methods 0.000 claims abstract description 261
- 230000007170 pathology Effects 0.000 claims abstract description 199
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 139
- 201000010099 disease Diseases 0.000 claims abstract description 137
- 238000005259 measurement Methods 0.000 claims abstract description 124
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 84
- 230000003176 fibrotic effect Effects 0.000 claims abstract description 66
- 238000003745 diagnosis Methods 0.000 claims abstract description 53
- 238000003384 imaging method Methods 0.000 claims description 140
- 230000033001 locomotion Effects 0.000 claims description 120
- 238000009792 diffusion process Methods 0.000 claims description 117
- 238000002595 magnetic resonance imaging Methods 0.000 claims description 75
- 210000000988 bone and bone Anatomy 0.000 claims description 70
- 210000004556 brain Anatomy 0.000 claims description 68
- 238000010801 machine learning Methods 0.000 claims description 63
- 230000006870 function Effects 0.000 claims description 50
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 46
- 208000024827 Alzheimer disease Diseases 0.000 claims description 43
- 201000006417 multiple sclerosis Diseases 0.000 claims description 43
- 238000002597 diffusion-weighted imaging Methods 0.000 claims description 37
- 238000009826 distribution Methods 0.000 claims description 36
- 238000004422 calculation algorithm Methods 0.000 claims description 35
- 239000000090 biomarker Substances 0.000 claims description 34
- 210000005166 vasculature Anatomy 0.000 claims description 34
- 238000012935 Averaging Methods 0.000 claims description 31
- 206010012289 Dementia Diseases 0.000 claims description 31
- 230000005284 excitation Effects 0.000 claims description 30
- 238000002598 diffusion tensor imaging Methods 0.000 claims description 28
- 210000004369 blood Anatomy 0.000 claims description 27
- 239000008280 blood Substances 0.000 claims description 27
- 238000001228 spectrum Methods 0.000 claims description 25
- 208000019423 liver disease Diseases 0.000 claims description 23
- 230000008569 process Effects 0.000 claims description 23
- 230000001537 neural effect Effects 0.000 claims description 20
- 210000004885 white matter Anatomy 0.000 claims description 19
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims description 18
- 230000002491 angiogenic effect Effects 0.000 claims description 18
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims description 18
- 238000012360 testing method Methods 0.000 claims description 17
- 238000012045 magnetic resonance elastography Methods 0.000 claims description 16
- 238000012805 post-processing Methods 0.000 claims description 16
- 238000000605 extraction Methods 0.000 claims description 15
- 230000005415 magnetization Effects 0.000 claims description 14
- 230000000977 initiatory effect Effects 0.000 claims description 13
- 208000019693 Lung disease Diseases 0.000 claims description 12
- 208000026106 cerebrovascular disease Diseases 0.000 claims description 12
- 230000001149 cognitive effect Effects 0.000 claims description 12
- 210000005013 brain tissue Anatomy 0.000 claims description 11
- 230000000747 cardiac effect Effects 0.000 claims description 11
- 208000019425 cirrhosis of liver Diseases 0.000 claims description 11
- 208000010877 cognitive disease Diseases 0.000 claims description 11
- 210000002966 serum Anatomy 0.000 claims description 11
- 238000004088 simulation Methods 0.000 claims description 11
- 230000001419 dependent effect Effects 0.000 claims description 10
- 208000029560 autism spectrum disease Diseases 0.000 claims description 9
- 230000009787 cardiac fibrosis Effects 0.000 claims description 9
- 238000002372 labelling Methods 0.000 claims description 9
- 238000000679 relaxometry Methods 0.000 claims description 9
- 238000012546 transfer Methods 0.000 claims description 9
- 208000019622 heart disease Diseases 0.000 claims description 8
- 230000002708 enhancing effect Effects 0.000 claims description 7
- 238000002075 inversion recovery Methods 0.000 claims description 7
- 238000005457 optimization Methods 0.000 claims description 7
- 208000018737 Parkinson disease Diseases 0.000 claims description 5
- 238000010603 microCT Methods 0.000 claims description 5
- 210000003205 muscle Anatomy 0.000 claims description 5
- 208000017497 prostate disease Diseases 0.000 claims description 5
- 201000000980 schizophrenia Diseases 0.000 claims description 5
- 238000004611 spectroscopical analysis Methods 0.000 claims description 5
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 4
- 210000005257 cortical tissue Anatomy 0.000 claims description 4
- 238000006213 oxygenation reaction Methods 0.000 claims description 4
- 238000000386 microscopy Methods 0.000 claims description 3
- 230000000926 neurological effect Effects 0.000 claims description 3
- 230000036314 physical performance Effects 0.000 claims description 3
- 208000023958 prostate neoplasm Diseases 0.000 claims description 2
- 230000000052 comparative effect Effects 0.000 claims 2
- 208000020446 Cardiac disease Diseases 0.000 claims 1
- 206010061296 Motor dysfunction Diseases 0.000 claims 1
- 210000000845 cartilage Anatomy 0.000 claims 1
- 238000003708 edge detection Methods 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 238000012544 monitoring process Methods 0.000 abstract description 22
- 238000012512 characterization method Methods 0.000 abstract description 18
- 238000001727 in vivo Methods 0.000 abstract description 18
- 230000002829 reductive effect Effects 0.000 abstract description 17
- 230000006378 damage Effects 0.000 abstract description 14
- 208000020084 Bone disease Diseases 0.000 abstract description 7
- 208000012902 Nervous system disease Diseases 0.000 abstract description 7
- 230000012010 growth Effects 0.000 abstract description 7
- 238000012307 MRI technique Methods 0.000 abstract 1
- 238000011161 development Methods 0.000 description 77
- 230000018109 developmental process Effects 0.000 description 76
- 239000000523 sample Substances 0.000 description 62
- 238000001574 biopsy Methods 0.000 description 50
- 238000001208 nuclear magnetic resonance pulse sequence Methods 0.000 description 48
- 230000003902 lesion Effects 0.000 description 47
- 210000000056 organ Anatomy 0.000 description 46
- 230000004044 response Effects 0.000 description 45
- 238000002560 therapeutic procedure Methods 0.000 description 40
- 230000008859 change Effects 0.000 description 38
- 230000001965 increasing effect Effects 0.000 description 38
- 230000000694 effects Effects 0.000 description 36
- 239000003550 marker Substances 0.000 description 29
- 230000001054 cortical effect Effects 0.000 description 28
- 230000015556 catabolic process Effects 0.000 description 27
- 238000006731 degradation reaction Methods 0.000 description 27
- 206010061818 Disease progression Diseases 0.000 description 25
- 230000000875 corresponding effect Effects 0.000 description 25
- 230000005750 disease progression Effects 0.000 description 25
- 210000004185 liver Anatomy 0.000 description 24
- 210000004072 lung Anatomy 0.000 description 24
- 230000007423 decrease Effects 0.000 description 23
- 206010016654 Fibrosis Diseases 0.000 description 22
- 102000006386 Myelin Proteins Human genes 0.000 description 20
- 108010083674 Myelin Proteins Proteins 0.000 description 20
- 210000005012 myelin Anatomy 0.000 description 20
- 230000004761 fibrosis Effects 0.000 description 19
- 239000000126 substance Substances 0.000 description 19
- 230000002596 correlated effect Effects 0.000 description 18
- 238000002592 echocardiography Methods 0.000 description 18
- 210000002307 prostate Anatomy 0.000 description 18
- 208000010392 Bone Fractures Diseases 0.000 description 17
- 206010061218 Inflammation Diseases 0.000 description 17
- 238000002591 computed tomography Methods 0.000 description 17
- 210000001320 hippocampus Anatomy 0.000 description 17
- 230000004054 inflammatory process Effects 0.000 description 17
- 230000010412 perfusion Effects 0.000 description 17
- 230000035945 sensitivity Effects 0.000 description 17
- 206010017076 Fracture Diseases 0.000 description 16
- 238000013459 approach Methods 0.000 description 15
- 230000037180 bone health Effects 0.000 description 15
- 238000011160 research Methods 0.000 description 15
- 239000002872 contrast media Substances 0.000 description 14
- 230000003247 decreasing effect Effects 0.000 description 13
- 238000011156 evaluation Methods 0.000 description 13
- 230000036541 health Effects 0.000 description 13
- 230000006872 improvement Effects 0.000 description 13
- 238000013507 mapping Methods 0.000 description 13
- 239000002207 metabolite Substances 0.000 description 13
- 102000008186 Collagen Human genes 0.000 description 12
- 108010035532 Collagen Proteins 0.000 description 12
- 208000016192 Demyelinating disease Diseases 0.000 description 12
- 206010012305 Demyelination Diseases 0.000 description 12
- 210000003484 anatomy Anatomy 0.000 description 12
- 229920001436 collagen Polymers 0.000 description 12
- 238000010586 diagram Methods 0.000 description 12
- 230000010363 phase shift Effects 0.000 description 12
- 238000012545 processing Methods 0.000 description 12
- 230000036962 time dependent Effects 0.000 description 12
- 206010003805 Autism Diseases 0.000 description 11
- 208000020706 Autistic disease Diseases 0.000 description 11
- 238000005481 NMR spectroscopy Methods 0.000 description 11
- 230000033115 angiogenesis Effects 0.000 description 11
- 201000011510 cancer Diseases 0.000 description 11
- 230000008520 organization Effects 0.000 description 11
- 230000009467 reduction Effects 0.000 description 11
- 230000002123 temporal effect Effects 0.000 description 11
- 206010060862 Prostate cancer Diseases 0.000 description 10
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 10
- 230000003376 axonal effect Effects 0.000 description 10
- 230000008901 benefit Effects 0.000 description 10
- 230000001413 cellular effect Effects 0.000 description 10
- 238000012937 correction Methods 0.000 description 10
- 238000001514 detection method Methods 0.000 description 10
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 9
- 206010030113 Oedema Diseases 0.000 description 9
- 208000004403 Prostatic Hyperplasia Diseases 0.000 description 9
- 210000003710 cerebral cortex Anatomy 0.000 description 9
- 238000009547 dual-energy X-ray absorptiometry Methods 0.000 description 9
- 239000000835 fiber Substances 0.000 description 9
- 230000036039 immunity Effects 0.000 description 9
- 238000013425 morphometry Methods 0.000 description 9
- 210000004165 myocardium Anatomy 0.000 description 9
- 210000002569 neuron Anatomy 0.000 description 9
- 230000001575 pathological effect Effects 0.000 description 9
- 208000024891 symptom Diseases 0.000 description 9
- 238000011282 treatment Methods 0.000 description 9
- 230000002792 vascular Effects 0.000 description 9
- 210000003050 axon Anatomy 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- 239000013626 chemical specie Substances 0.000 description 8
- 230000001010 compromised effect Effects 0.000 description 8
- 238000006073 displacement reaction Methods 0.000 description 8
- 210000001353 entorhinal cortex Anatomy 0.000 description 8
- 238000005755 formation reaction Methods 0.000 description 8
- 210000004088 microvessel Anatomy 0.000 description 8
- 230000000750 progressive effect Effects 0.000 description 8
- 230000003595 spectral effect Effects 0.000 description 8
- 230000008685 targeting Effects 0.000 description 8
- 208000003174 Brain Neoplasms Diseases 0.000 description 7
- 229910052688 Gadolinium Inorganic materials 0.000 description 7
- 230000002159 abnormal effect Effects 0.000 description 7
- 230000002411 adverse Effects 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 7
- 230000017531 blood circulation Effects 0.000 description 7
- 230000007850 degeneration Effects 0.000 description 7
- UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 description 7
- 210000004884 grey matter Anatomy 0.000 description 7
- 208000014674 injury Diseases 0.000 description 7
- 239000011159 matrix material Substances 0.000 description 7
- 230000000451 tissue damage Effects 0.000 description 7
- 231100000827 tissue damage Toxicity 0.000 description 7
- 206010028594 Myocardial fibrosis Diseases 0.000 description 6
- 208000001132 Osteoporosis Diseases 0.000 description 6
- 208000006011 Stroke Diseases 0.000 description 6
- 208000027418 Wounds and injury Diseases 0.000 description 6
- 239000000654 additive Substances 0.000 description 6
- 230000000996 additive effect Effects 0.000 description 6
- 230000032683 aging Effects 0.000 description 6
- 230000000295 complement effect Effects 0.000 description 6
- 238000000151 deposition Methods 0.000 description 6
- 230000008021 deposition Effects 0.000 description 6
- 230000001939 inductive effect Effects 0.000 description 6
- 230000003993 interaction Effects 0.000 description 6
- 230000009021 linear effect Effects 0.000 description 6
- 230000004807 localization Effects 0.000 description 6
- 230000003562 morphometric effect Effects 0.000 description 6
- 210000000478 neocortex Anatomy 0.000 description 6
- 230000036285 pathological change Effects 0.000 description 6
- 238000002600 positron emission tomography Methods 0.000 description 6
- 206010003694 Atrophy Diseases 0.000 description 5
- 206010006187 Breast cancer Diseases 0.000 description 5
- 208000026310 Breast neoplasm Diseases 0.000 description 5
- 230000037444 atrophy Effects 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 230000003727 cerebral blood flow Effects 0.000 description 5
- 230000006999 cognitive decline Effects 0.000 description 5
- 238000013461 design Methods 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 239000012530 fluid Substances 0.000 description 5
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 5
- 230000002440 hepatic effect Effects 0.000 description 5
- 230000009545 invasion Effects 0.000 description 5
- 210000005228 liver tissue Anatomy 0.000 description 5
- 230000007171 neuropathology Effects 0.000 description 5
- 230000001009 osteoporotic effect Effects 0.000 description 5
- 230000001717 pathogenic effect Effects 0.000 description 5
- 238000004393 prognosis Methods 0.000 description 5
- 230000005855 radiation Effects 0.000 description 5
- 230000000241 respiratory effect Effects 0.000 description 5
- 230000035882 stress Effects 0.000 description 5
- 238000002604 ultrasonography Methods 0.000 description 5
- ZCXUVYAZINUVJD-AHXZWLDOSA-N 2-deoxy-2-((18)F)fluoro-alpha-D-glucose Chemical compound OC[C@H]1O[C@H](O)[C@H]([18F])[C@@H](O)[C@@H]1O ZCXUVYAZINUVJD-AHXZWLDOSA-N 0.000 description 4
- 206010061728 Bone lesion Diseases 0.000 description 4
- 208000024806 Brain atrophy Diseases 0.000 description 4
- 208000004051 Chronic Traumatic Encephalopathy Diseases 0.000 description 4
- 201000003883 Cystic fibrosis Diseases 0.000 description 4
- 102000007066 Prostate-Specific Antigen Human genes 0.000 description 4
- 108010072866 Prostate-Specific Antigen Proteins 0.000 description 4
- 208000030886 Traumatic Brain injury Diseases 0.000 description 4
- 230000001154 acute effect Effects 0.000 description 4
- 230000007792 alzheimer disease pathology Effects 0.000 description 4
- 230000003466 anti-cipated effect Effects 0.000 description 4
- 238000005311 autocorrelation function Methods 0.000 description 4
- 230000006399 behavior Effects 0.000 description 4
- 210000000481 breast Anatomy 0.000 description 4
- 210000003169 central nervous system Anatomy 0.000 description 4
- 210000003618 cortical neuron Anatomy 0.000 description 4
- 208000017004 dementia pugilistica Diseases 0.000 description 4
- 238000002405 diagnostic procedure Methods 0.000 description 4
- 230000004069 differentiation Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 238000011049 filling Methods 0.000 description 4
- 230000002068 genetic effect Effects 0.000 description 4
- 239000005337 ground glass Substances 0.000 description 4
- 230000035876 healing Effects 0.000 description 4
- 230000000971 hippocampal effect Effects 0.000 description 4
- 239000001257 hydrogen Substances 0.000 description 4
- 229910052739 hydrogen Inorganic materials 0.000 description 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 4
- 238000011835 investigation Methods 0.000 description 4
- 230000000670 limiting effect Effects 0.000 description 4
- 229920002521 macromolecule Polymers 0.000 description 4
- 230000006996 mental state Effects 0.000 description 4
- 230000002503 metabolic effect Effects 0.000 description 4
- 208000027061 mild cognitive impairment Diseases 0.000 description 4
- 230000002107 myocardial effect Effects 0.000 description 4
- 230000001613 neoplastic effect Effects 0.000 description 4
- 210000005036 nerve Anatomy 0.000 description 4
- 230000036961 partial effect Effects 0.000 description 4
- 230000035699 permeability Effects 0.000 description 4
- 230000002250 progressing effect Effects 0.000 description 4
- 230000001629 suppression Effects 0.000 description 4
- 238000001356 surgical procedure Methods 0.000 description 4
- 230000009529 traumatic brain injury Effects 0.000 description 4
- 238000012800 visualization Methods 0.000 description 4
- 208000014644 Brain disease Diseases 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- 206010028347 Muscle twitching Diseases 0.000 description 3
- 238000012879 PET imaging Methods 0.000 description 3
- 238000002441 X-ray diffraction Methods 0.000 description 3
- 210000004712 air sac Anatomy 0.000 description 3
- 230000004075 alteration Effects 0.000 description 3
- 239000012472 biological sample Substances 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 210000001185 bone marrow Anatomy 0.000 description 3
- 230000002490 cerebral effect Effects 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 230000007882 cirrhosis Effects 0.000 description 3
- 230000001747 exhibiting effect Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 210000003414 extremity Anatomy 0.000 description 3
- 238000004868 gas analysis Methods 0.000 description 3
- 230000000762 glandular Effects 0.000 description 3
- 230000004153 glucose metabolism Effects 0.000 description 3
- 238000009499 grossing Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- 230000001423 neocortical effect Effects 0.000 description 3
- 230000009022 nonlinear effect Effects 0.000 description 3
- 230000009325 pulmonary function Effects 0.000 description 3
- 230000000541 pulsatile effect Effects 0.000 description 3
- 239000000700 radioactive tracer Substances 0.000 description 3
- 238000012552 review Methods 0.000 description 3
- 239000011435 rock Substances 0.000 description 3
- 238000010408 sweeping Methods 0.000 description 3
- 238000012549 training Methods 0.000 description 3
- 230000007704 transition Effects 0.000 description 3
- 230000005748 tumor development Effects 0.000 description 3
- 230000004614 tumor growth Effects 0.000 description 3
- 230000032665 vasculature development Effects 0.000 description 3
- 238000010176 18-FDG-positron emission tomography Methods 0.000 description 2
- 208000000044 Amnesia Diseases 0.000 description 2
- 230000005653 Brownian motion process Effects 0.000 description 2
- 208000027647 Cerebral Cortical Thinning Diseases 0.000 description 2
- 208000028698 Cognitive impairment Diseases 0.000 description 2
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 description 2
- 206010067889 Dementia with Lewy bodies Diseases 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- 206010018338 Glioma Diseases 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 208000023105 Huntington disease Diseases 0.000 description 2
- 208000029523 Interstitial Lung disease Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 206010065973 Iron Overload Diseases 0.000 description 2
- 208000032382 Ischaemic stroke Diseases 0.000 description 2
- 201000002832 Lewy body dementia Diseases 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 208000026139 Memory disease Diseases 0.000 description 2
- OTCCIMWXFLJLIA-UHFFFAOYSA-N N-acetyl-DL-aspartic acid Natural products CC(=O)NC(C(O)=O)CC(O)=O OTCCIMWXFLJLIA-UHFFFAOYSA-N 0.000 description 2
- OTCCIMWXFLJLIA-BYPYZUCNSA-N N-acetyl-L-aspartic acid Chemical compound CC(=O)N[C@H](C(O)=O)CC(O)=O OTCCIMWXFLJLIA-BYPYZUCNSA-N 0.000 description 2
- 208000009668 Neurobehavioral Manifestations Diseases 0.000 description 2
- 206010056342 Pulmonary mass Diseases 0.000 description 2
- 208000016247 Soft tissue disease Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000035508 accumulation Effects 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 230000003679 aging effect Effects 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 230000008499 blood brain barrier function Effects 0.000 description 2
- 238000009534 blood test Methods 0.000 description 2
- 210000001218 blood-brain barrier Anatomy 0.000 description 2
- 238000007470 bone biopsy Methods 0.000 description 2
- 230000037182 bone density Effects 0.000 description 2
- 230000037118 bone strength Effects 0.000 description 2
- 238000005537 brownian motion Methods 0.000 description 2
- 230000010351 cardiac pulsation Effects 0.000 description 2
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 2
- 230000000739 chaotic effect Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 230000019771 cognition Effects 0.000 description 2
- 230000001427 coherent effect Effects 0.000 description 2
- 210000002808 connective tissue Anatomy 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 2
- 238000005034 decoration Methods 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 238000012631 diagnostic technique Methods 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000003628 erosive effect Effects 0.000 description 2
- 210000002744 extracellular matrix Anatomy 0.000 description 2
- 239000004744 fabric Substances 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 208000036449 fibrotic liver disease Diseases 0.000 description 2
- 238000002599 functional magnetic resonance imaging Methods 0.000 description 2
- 230000004190 glucose uptake Effects 0.000 description 2
- 230000004217 heart function Effects 0.000 description 2
- 238000010191 image analysis Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 2
- 229960000367 inositol Drugs 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000005865 ionizing radiation Effects 0.000 description 2
- 230000002427 irreversible effect Effects 0.000 description 2
- 208000028867 ischemia Diseases 0.000 description 2
- 230000000302 ischemic effect Effects 0.000 description 2
- 208000017169 kidney disease Diseases 0.000 description 2
- 238000012317 liver biopsy Methods 0.000 description 2
- 238000007449 liver function test Methods 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 230000002101 lytic effect Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000000691 measurement method Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000006984 memory degeneration Effects 0.000 description 2
- 208000023060 memory loss Diseases 0.000 description 2
- 230000004066 metabolic change Effects 0.000 description 2
- 230000004089 microcirculation Effects 0.000 description 2
- 230000003278 mimic effect Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000000877 morphologic effect Effects 0.000 description 2
- 230000003387 muscular Effects 0.000 description 2
- 201000006938 muscular dystrophy Diseases 0.000 description 2
- 206010028537 myelofibrosis Diseases 0.000 description 2
- 238000013188 needle biopsy Methods 0.000 description 2
- 238000002610 neuroimaging Methods 0.000 description 2
- 230000003961 neuronal insult Effects 0.000 description 2
- 239000000101 novel biomarker Substances 0.000 description 2
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 2
- 230000000771 oncological effect Effects 0.000 description 2
- 238000011275 oncology therapy Methods 0.000 description 2
- 230000010355 oscillation Effects 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 238000000059 patterning Methods 0.000 description 2
- 208000007232 portal hypertension Diseases 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 208000005069 pulmonary fibrosis Diseases 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 230000003252 repetitive effect Effects 0.000 description 2
- 230000037390 scarring Effects 0.000 description 2
- 230000002784 sclerotic effect Effects 0.000 description 2
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 2
- 230000011218 segmentation Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 238000004904 shortening Methods 0.000 description 2
- 210000004872 soft tissue Anatomy 0.000 description 2
- 238000000264 spin echo pulse sequence Methods 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 230000003068 static effect Effects 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 230000009897 systematic effect Effects 0.000 description 2
- 208000026533 urinary bladder disease Diseases 0.000 description 2
- 238000010200 validation analysis Methods 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 208000037259 Amyloid Plaque Diseases 0.000 description 1
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 description 1
- 206010005949 Bone cancer Diseases 0.000 description 1
- 208000018084 Bone neoplasm Diseases 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 208000031229 Cardiomyopathies Diseases 0.000 description 1
- 208000015374 Central core disease Diseases 0.000 description 1
- 206010051290 Central nervous system lesion Diseases 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- 208000006154 Chronic hepatitis C Diseases 0.000 description 1
- 206010071068 Clinically isolated syndrome Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 208000030814 Eating disease Diseases 0.000 description 1
- 208000019454 Feeding and Eating disease Diseases 0.000 description 1
- 206010016454 Femur fracture Diseases 0.000 description 1
- 201000011240 Frontotemporal dementia Diseases 0.000 description 1
- 206010018341 Gliosis Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 206010019669 Hepatic fibrosis and cirrhosis Diseases 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 201000003838 Idiopathic interstitial pneumonia Diseases 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 208000019430 Motor disease Diseases 0.000 description 1
- 208000029578 Muscle disease Diseases 0.000 description 1
- 206010048654 Muscle fibrosis Diseases 0.000 description 1
- 238000012565 NMR experiment Methods 0.000 description 1
- 208000011623 Obstructive Lung disease Diseases 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 206010072360 Peritumoural oedema Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 208000037048 Prodromal Symptoms Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 206010064390 Tumour invasion Diseases 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 206010072731 White matter lesion Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 210000002821 alveolar epithelial cell Anatomy 0.000 description 1
- 238000002583 angiography Methods 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 210000003926 auditory cortex Anatomy 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000008081 blood perfusion Effects 0.000 description 1
- 238000002725 brachytherapy Methods 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 230000009400 cancer invasion Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 210000001054 cardiac fibroblast Anatomy 0.000 description 1
- 230000006727 cell loss Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 201000007303 central core myopathy Diseases 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 229940121657 clinical drug Drugs 0.000 description 1
- 230000003930 cognitive ability Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 238000005094 computer simulation Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000005314 correlation function Methods 0.000 description 1
- 230000007591 cortical connectivity Effects 0.000 description 1
- 230000009509 cortical damage Effects 0.000 description 1
- 229960003624 creatine Drugs 0.000 description 1
- 239000006046 creatine Substances 0.000 description 1
- 238000002681 cryosurgery Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 238000013480 data collection Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000013135 deep learning Methods 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 238000000326 densiometry Methods 0.000 description 1
- 238000003748 differential diagnosis Methods 0.000 description 1
- 235000014632 disordered eating Nutrition 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 206010013932 dyslexia Diseases 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 238000002091 elastography Methods 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 208000020089 femoral neck fracture Diseases 0.000 description 1
- 230000003328 fibroblastic effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 210000005153 frontal cortex Anatomy 0.000 description 1
- 230000002518 glial effect Effects 0.000 description 1
- 230000007387 gliosis Effects 0.000 description 1
- 230000005182 global health Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229960001031 glucose Drugs 0.000 description 1
- 230000036433 growing body Effects 0.000 description 1
- 210000004326 gyrus cinguli Anatomy 0.000 description 1
- 230000005986 heart dysfunction Effects 0.000 description 1
- 208000010710 hepatitis C virus infection Diseases 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 230000002962 histologic effect Effects 0.000 description 1
- 230000000899 immune system response Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 238000011503 in vivo imaging Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 238000013101 initial test Methods 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 238000002721 intensity-modulated radiation therapy Methods 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 230000002262 irrigation Effects 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 210000005240 left ventricle Anatomy 0.000 description 1
- 238000011528 liquid biopsy Methods 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 230000004199 lung function Effects 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 238000007620 mathematical function Methods 0.000 description 1
- 238000012067 mathematical method Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 210000003007 myelin sheath Anatomy 0.000 description 1
- 210000000651 myofibroblast Anatomy 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 230000003121 nonmonotonic effect Effects 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 238000004223 overdiagnosis Methods 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 238000003909 pattern recognition Methods 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 210000003240 portal vein Anatomy 0.000 description 1
- 230000002360 prefrontal effect Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000007425 progressive decline Effects 0.000 description 1
- 208000037821 progressive disease Diseases 0.000 description 1
- 210000001176 projection neuron Anatomy 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 201000001514 prostate carcinoma Diseases 0.000 description 1
- 201000007094 prostatitis Diseases 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 210000003456 pulmonary alveoli Anatomy 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 238000009738 saturating Methods 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 238000012883 sequential measurement Methods 0.000 description 1
- 210000003625 skull Anatomy 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 206010041569 spinal fracture Diseases 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000005654 stationary process Effects 0.000 description 1
- 230000007863 steatosis Effects 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 210000001562 sternum Anatomy 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000008354 tissue degradation Effects 0.000 description 1
- 230000009772 tissue formation Effects 0.000 description 1
- 208000037816 tissue injury Diseases 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 230000005747 tumor angiogenesis Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000005740 tumor formation Effects 0.000 description 1
- 238000012285 ultrasound imaging Methods 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 230000006438 vascular health Effects 0.000 description 1
- 230000006439 vascular pathology Effects 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 238000010626 work up procedure Methods 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01R—MEASURING ELECTRIC VARIABLES; MEASURING MAGNETIC VARIABLES
- G01R33/00—Arrangements or instruments for measuring magnetic variables
- G01R33/20—Arrangements or instruments for measuring magnetic variables involving magnetic resonance
- G01R33/44—Arrangements or instruments for measuring magnetic variables involving magnetic resonance using nuclear magnetic resonance [NMR]
- G01R33/48—NMR imaging systems
- G01R33/4818—MR characterised by data acquisition along a specific k-space trajectory or by the temporal order of k-space coverage, e.g. centric or segmented coverage of k-space
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/05—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves
- A61B5/055—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01R—MEASURING ELECTRIC VARIABLES; MEASURING MAGNETIC VARIABLES
- G01R33/00—Arrangements or instruments for measuring magnetic variables
- G01R33/20—Arrangements or instruments for measuring magnetic variables involving magnetic resonance
- G01R33/44—Arrangements or instruments for measuring magnetic variables involving magnetic resonance using nuclear magnetic resonance [NMR]
- G01R33/48—NMR imaging systems
- G01R33/483—NMR imaging systems with selection of signals or spectra from particular regions of the volume, e.g. in vivo spectroscopy
- G01R33/4833—NMR imaging systems with selection of signals or spectra from particular regions of the volume, e.g. in vivo spectroscopy using spatially selective excitation of the volume of interest, e.g. selecting non-orthogonal or inclined slices
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/48—Other medical applications
- A61B5/4842—Monitoring progression or stage of a disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01R—MEASURING ELECTRIC VARIABLES; MEASURING MAGNETIC VARIABLES
- G01R33/00—Arrangements or instruments for measuring magnetic variables
- G01R33/20—Arrangements or instruments for measuring magnetic variables involving magnetic resonance
- G01R33/44—Arrangements or instruments for measuring magnetic variables involving magnetic resonance using nuclear magnetic resonance [NMR]
- G01R33/48—NMR imaging systems
- G01R33/4818—MR characterised by data acquisition along a specific k-space trajectory or by the temporal order of k-space coverage, e.g. centric or segmented coverage of k-space
- G01R33/482—MR characterised by data acquisition along a specific k-space trajectory or by the temporal order of k-space coverage, e.g. centric or segmented coverage of k-space using a Cartesian trajectory
- G01R33/4822—MR characterised by data acquisition along a specific k-space trajectory or by the temporal order of k-space coverage, e.g. centric or segmented coverage of k-space using a Cartesian trajectory in three dimensions
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01R—MEASURING ELECTRIC VARIABLES; MEASURING MAGNETIC VARIABLES
- G01R33/00—Arrangements or instruments for measuring magnetic variables
- G01R33/20—Arrangements or instruments for measuring magnetic variables involving magnetic resonance
- G01R33/44—Arrangements or instruments for measuring magnetic variables involving magnetic resonance using nuclear magnetic resonance [NMR]
- G01R33/48—NMR imaging systems
- G01R33/54—Signal processing systems, e.g. using pulse sequences ; Generation or control of pulse sequences; Operator console
- G01R33/56—Image enhancement or correction, e.g. subtraction or averaging techniques, e.g. improvement of signal-to-noise ratio and resolution
- G01R33/5601—Image enhancement or correction, e.g. subtraction or averaging techniques, e.g. improvement of signal-to-noise ratio and resolution involving use of a contrast agent for contrast manipulation, e.g. a paramagnetic, super-paramagnetic, ferromagnetic or hyperpolarised contrast agent
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01R—MEASURING ELECTRIC VARIABLES; MEASURING MAGNETIC VARIABLES
- G01R33/00—Arrangements or instruments for measuring magnetic variables
- G01R33/20—Arrangements or instruments for measuring magnetic variables involving magnetic resonance
- G01R33/44—Arrangements or instruments for measuring magnetic variables involving magnetic resonance using nuclear magnetic resonance [NMR]
- G01R33/48—NMR imaging systems
- G01R33/54—Signal processing systems, e.g. using pulse sequences ; Generation or control of pulse sequences; Operator console
- G01R33/56—Image enhancement or correction, e.g. subtraction or averaging techniques, e.g. improvement of signal-to-noise ratio and resolution
- G01R33/5602—Image enhancement or correction, e.g. subtraction or averaging techniques, e.g. improvement of signal-to-noise ratio and resolution by filtering or weighting based on different relaxation times within the sample, e.g. T1 weighting using an inversion pulse
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01R—MEASURING ELECTRIC VARIABLES; MEASURING MAGNETIC VARIABLES
- G01R33/00—Arrangements or instruments for measuring magnetic variables
- G01R33/20—Arrangements or instruments for measuring magnetic variables involving magnetic resonance
- G01R33/44—Arrangements or instruments for measuring magnetic variables involving magnetic resonance using nuclear magnetic resonance [NMR]
- G01R33/48—NMR imaging systems
- G01R33/54—Signal processing systems, e.g. using pulse sequences ; Generation or control of pulse sequences; Operator console
- G01R33/56—Image enhancement or correction, e.g. subtraction or averaging techniques, e.g. improvement of signal-to-noise ratio and resolution
- G01R33/5605—Image enhancement or correction, e.g. subtraction or averaging techniques, e.g. improvement of signal-to-noise ratio and resolution by transferring coherence or polarization from a spin species to another, e.g. creating magnetization transfer contrast [MTC], polarization transfer using nuclear Overhauser enhancement [NOE]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01R—MEASURING ELECTRIC VARIABLES; MEASURING MAGNETIC VARIABLES
- G01R33/00—Arrangements or instruments for measuring magnetic variables
- G01R33/20—Arrangements or instruments for measuring magnetic variables involving magnetic resonance
- G01R33/44—Arrangements or instruments for measuring magnetic variables involving magnetic resonance using nuclear magnetic resonance [NMR]
- G01R33/48—NMR imaging systems
- G01R33/54—Signal processing systems, e.g. using pulse sequences ; Generation or control of pulse sequences; Operator console
- G01R33/56—Image enhancement or correction, e.g. subtraction or averaging techniques, e.g. improvement of signal-to-noise ratio and resolution
- G01R33/561—Image enhancement or correction, e.g. subtraction or averaging techniques, e.g. improvement of signal-to-noise ratio and resolution by reduction of the scanning time, i.e. fast acquiring systems, e.g. using echo-planar pulse sequences
- G01R33/5615—Echo train techniques involving acquiring plural, differently encoded, echo signals after one RF excitation, e.g. using gradient refocusing in echo planar imaging [EPI], RF refocusing in rapid acquisition with relaxation enhancement [RARE] or using both RF and gradient refocusing in gradient and spin echo imaging [GRASE]
- G01R33/5617—Echo train techniques involving acquiring plural, differently encoded, echo signals after one RF excitation, e.g. using gradient refocusing in echo planar imaging [EPI], RF refocusing in rapid acquisition with relaxation enhancement [RARE] or using both RF and gradient refocusing in gradient and spin echo imaging [GRASE] using RF refocusing, e.g. RARE
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01R—MEASURING ELECTRIC VARIABLES; MEASURING MAGNETIC VARIABLES
- G01R33/00—Arrangements or instruments for measuring magnetic variables
- G01R33/20—Arrangements or instruments for measuring magnetic variables involving magnetic resonance
- G01R33/44—Arrangements or instruments for measuring magnetic variables involving magnetic resonance using nuclear magnetic resonance [NMR]
- G01R33/48—NMR imaging systems
- G01R33/54—Signal processing systems, e.g. using pulse sequences ; Generation or control of pulse sequences; Operator console
- G01R33/56—Image enhancement or correction, e.g. subtraction or averaging techniques, e.g. improvement of signal-to-noise ratio and resolution
- G01R33/563—Image enhancement or correction, e.g. subtraction or averaging techniques, e.g. improvement of signal-to-noise ratio and resolution of moving material, e.g. flow contrast angiography
- G01R33/56341—Diffusion imaging
Landscapes
- Physics & Mathematics (AREA)
- Health & Medical Sciences (AREA)
- High Energy & Nuclear Physics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Physics & Mathematics (AREA)
- Condensed Matter Physics & Semiconductors (AREA)
- Heart & Thoracic Surgery (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Pathology (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- Surgery (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Radiology & Medical Imaging (AREA)
- Optics & Photonics (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Magnetic Resonance Imaging Apparatus (AREA)
Abstract
Conformément à des modes de réalisation, la présente invention concerne un procédé pour l'acquisition de données de résonance magnétique (RM) à des résolutions pouvant descendre jusqu'à des dizaines de microns pour une application en diagnostic in vivo et la surveillance d'une pathologie pour laquelle des modifications de fines textures tissulaires peuvent être utilisées comme marqueurs d'apparition et de progression d'une maladie. Les maladies osseuses, les tumeurs, les maladies neurologiques et les maladies impliquant la croissance fibreuse et/ou la destruction des fibres sont toutes des pathologies cibles. En outre, la technique peut être utilisée dans n'importe quel système biologique ou physique pour lequel une caractérisation à très haute résolution d'une morphologie à petite échelle est nécessaire. Le procédé permet l'acquisition rapide d'un signal à des valeurs sélectionnées dans l'espace k, avec de multiples acquisitions successives à des valeurs k individuelles prises sur une échelle de temps de l'ordre de la microseconde, dans un volume de tissu défini, et la combinaison ultérieure des multiples mesures de façon à rendre maximal le rapport signal sur bruit (SNR). Le volume d'acquisition réduit et l'acquisition uniquement de valeurs de signal à des endroits sélectionnés dans l'espace k, le long de directions sélectionnées, permettent une résolution in vivo bien plus élevée que celle qui pourrait être obtenue avec les techniques d'imagerie par résonance magnétique (IRM) actuelles.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15/604,465 | 2017-05-24 | ||
| US15/604,465 US10061003B2 (en) | 2014-09-01 | 2017-05-24 | Selective sampling for assessing structural spatial frequencies with specific contrast mechanisms |
| PCT/US2018/033727 WO2018217658A1 (fr) | 2017-05-24 | 2018-05-21 | Échantillonnage sélectif pour évaluer des fréquences spatiales structurales avec des mécanismes de contraste spécifiques |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3064736A1 true CA3064736A1 (fr) | 2018-11-29 |
Family
ID=64396914
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3064736A Pending CA3064736A1 (fr) | 2017-05-24 | 2018-05-21 | Echantillonnage selectif pour evaluer des frequences spatiales structurales avec des mecanismes de contraste specifiques |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP3629915A4 (fr) |
| JP (1) | JP7273803B2 (fr) |
| CN (1) | CN110958854A (fr) |
| AU (1) | AU2018273362A1 (fr) |
| CA (1) | CA3064736A1 (fr) |
| WO (1) | WO2018217658A1 (fr) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111803068A (zh) * | 2020-08-21 | 2020-10-23 | 上海中医药大学附属曙光医院 | 一种基于虚拟磁共振弹性成像的无创评估肝纤维化的方法 |
| CN113156350B (zh) * | 2021-03-25 | 2022-07-19 | 华南理工大学 | 无创光不透明微米级活体组织磁共振断层成像方法及系统 |
| CN114371232B (zh) * | 2021-12-22 | 2024-03-22 | 天津国科医工科技发展有限公司 | 基于卡尔曼滤波算法的色谱滤波方法、装置、介质、系统 |
| CN114708973B (zh) * | 2022-06-06 | 2022-09-13 | 首都医科大学附属北京友谊医院 | 一种用于对人体健康进行评估的设备和存储介质 |
| CN116934757B (zh) * | 2023-09-18 | 2023-11-21 | 电子科技大学 | 一种用于肺结节假阳性删减的方法、设备及存储介质 |
| CN117388672B (zh) * | 2023-12-11 | 2024-04-19 | 四川睿杰鑫电子股份有限公司 | 一种电路板用电源通路检测装置及其检测方法 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3393895B2 (ja) * | 1993-09-13 | 2003-04-07 | 株式会社東芝 | 磁気共鳴映像装置 |
| JP4265855B2 (ja) | 2000-05-31 | 2009-05-20 | 株式会社日立メディコ | 磁気共鳴イメージング装置 |
| US6320380B1 (en) * | 2000-10-03 | 2001-11-20 | Marconi Medical Systems, Inc. | MRI method and apparatus for increasing the efficiency of echo lanar imaging and other late echo techniques |
| CA2535942A1 (fr) | 2003-08-21 | 2005-03-10 | Ischem Corporation | Techniques et systemes automatises de detection et d'analyse de plaque vasculaire |
| DE102004017852B4 (de) | 2004-04-13 | 2008-11-27 | Siemens Ag | Bewegungskorrigiertes Multi-Shot-Verfahren zur diffusionsgewichteten Bildgebung in der Magnetresonanztomographie |
| US8057408B2 (en) * | 2005-09-22 | 2011-11-15 | The Regents Of The University Of Michigan | Pulsed cavitational ultrasound therapy |
| RU2423718C2 (ru) * | 2005-11-27 | 2011-07-10 | Эквитас Медикал Лимитед | Оценивание структуры с использованием пространственно-частотного анализа |
| JP4993960B2 (ja) | 2006-07-11 | 2012-08-08 | 株式会社日立メディコ | 核磁気共鳴撮像装置 |
| WO2008034845A2 (fr) | 2006-09-19 | 2008-03-27 | Nordic Bioscience Imaging A/S | Mesure indiquant une pathologie liée à une structure de cartilage et quantification automatique de celle-ci |
| US20100145185A1 (en) * | 2008-12-04 | 2010-06-10 | Xiaole Hong | Extending the resolution of mri data by combining subsets from plural image acquisitions |
| JP5360757B2 (ja) * | 2009-04-22 | 2013-12-04 | 独立行政法人情報通信研究機構 | 磁気共鳴画像法および磁気共鳴画像装置 |
| JP5442490B2 (ja) | 2010-02-26 | 2014-03-12 | ジーイー・メディカル・システムズ・グローバル・テクノロジー・カンパニー・エルエルシー | 磁気共鳴イメージング装置 |
| US8966701B2 (en) * | 2012-06-14 | 2015-03-03 | Joseph Dellecave | Sole wipe |
| WO2014130813A1 (fr) * | 2013-02-21 | 2014-08-28 | New York University | Procédé et dispositif de quantification précise de temps t2 de relaxation en fonction de séquences rapides de rmn à écho de spin multiple |
| US9366740B2 (en) * | 2013-03-14 | 2016-06-14 | Wisconsin Alumni Research Foundation | System and method for vastly undersampled isotropic projection reconstruction with inversion recovery |
| JP5762460B2 (ja) | 2013-04-11 | 2015-08-12 | ジーイー・メディカル・システムズ・グローバル・テクノロジー・カンパニー・エルエルシー | 磁気共鳴装置およびプログラム |
| WO2015092622A2 (fr) * | 2013-12-20 | 2015-06-25 | Koninklijke Philips N.V. | Génération d'une carte d'atténuation guidée de densité dans des systèmes pet/rm |
| US9664759B2 (en) * | 2014-09-01 | 2017-05-30 | bioProtonics, L.L.C | Method for assessing structural spatial frequencies using hybrid sampling with non-zero gradient for enhancement of selective sampling |
| US9664760B2 (en) | 2014-09-01 | 2017-05-30 | bioProtonics, L.L.C | Selective sampling for assessing structural spatial frequencies with specific contrast mechanisms |
| US9655522B2 (en) * | 2014-10-10 | 2017-05-23 | Cedars-Sinai Medical Center | Method and system for “push-button” comprehensive cardiac MR examination using continuous self-gated 3D radial imaging |
| JP6576726B2 (ja) | 2015-07-24 | 2019-09-18 | ジーイー・メディカル・システムズ・グローバル・テクノロジー・カンパニー・エルエルシー | 磁気共鳴装置 |
| EP3359034A4 (fr) | 2015-10-07 | 2019-08-07 | Bioprotonics, Inc. | Échantillonnage sélectif pour évaluer des fréquences spatiales structurales avec des mécanismes de contraste spécifiques |
-
2018
- 2018-05-21 AU AU2018273362A patent/AU2018273362A1/en not_active Abandoned
- 2018-05-21 WO PCT/US2018/033727 patent/WO2018217658A1/fr unknown
- 2018-05-21 CN CN201880049872.3A patent/CN110958854A/zh active Pending
- 2018-05-21 EP EP18805648.5A patent/EP3629915A4/fr not_active Withdrawn
- 2018-05-21 JP JP2020516380A patent/JP7273803B2/ja active Active
- 2018-05-21 CA CA3064736A patent/CA3064736A1/fr active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN110958854A (zh) | 2020-04-03 |
| EP3629915A1 (fr) | 2020-04-08 |
| WO2018217658A1 (fr) | 2018-11-29 |
| EP3629915A4 (fr) | 2021-03-03 |
| JP2020520786A (ja) | 2020-07-16 |
| AU2018273362A1 (en) | 2020-01-23 |
| JP7273803B2 (ja) | 2023-05-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11175363B2 (en) | Selective sampling for assessing structural spatial frequencies with specific contrast mechanisms | |
| AU2016334250B2 (en) | Selective sampling for assessing structural spatial frequencies with specific contrast mechanisms | |
| US9664760B2 (en) | Selective sampling for assessing structural spatial frequencies with specific contrast mechanisms | |
| AU2021201998B2 (en) | Selective sampling magnetic resonance-based method for assessing structural spatial frequencies | |
| JP7273803B2 (ja) | 特定のコントラスト機構を用いて構造的空間周波数を評価するための選択的サンプリング | |
| Charles-Edwards et al. | Diffusion-weighted magnetic resonance imaging and its application to cancer | |
| US9664759B2 (en) | Method for assessing structural spatial frequencies using hybrid sampling with non-zero gradient for enhancement of selective sampling | |
| Reischauer et al. | High-resolution diffusion tensor imaging of prostate cancer using a reduced FOV technique | |
| US20190056470A1 (en) | Methods and devices for contrast agent magnetic resonance imaging | |
| US10215827B2 (en) | Method to measure tissue texture using NMR spectroscopy to identify the chemical species of component textural elements in a targeted region of tissue | |
| US20090185981A1 (en) | Methods and apparatus for dynamically allocating bandwidth to spectral, temporal, and spatial dimensions during a magnetic resonance imaging procedure | |
| Mendez et al. | Diffusion breast MRI: current standard and emerging techniques | |
| AU2018297168A1 (en) | A method to measure tissue texture using NMR spectroscopy to identify chemical species of component textural elements in a targeted region of tissue | |
| Hernando et al. | Quantitative diffusion MRI of the abdomen and pelvis | |
| Mostardeiro et al. | Whole-brain 3D MR fingerprinting brain imaging: clinical validation and feasibility to patients with meningioma | |
| Dan et al. | Time‐dependent diffusion MRI using multiple stimulated echoes | |
| Nunes et al. | Diffusion mri outside the brain | |
| Sperling et al. | Diffusion-Weighted Whole-Body Imaging: Tumor Staging Applications |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20230516 |
|
| EEER | Examination request |
Effective date: 20230516 |